Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemiplimab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cemiplimab (REGN2810, also known as SAR439684) is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to enhance T-cell mediated immune responses against cancer cells. Ipilimumab is a monoclonal antibody that targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), another immune checkpoint, thereby promoting T-cell activation and proliferation. The combination of cemiplimab and ipilimumab is being investigated for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and other cancers. This combination aims to provide synergistic enhancement of anti-tumor immunity by dual checkpoint inhibition. Cemiplimab was developed by Regeneron Pharmaceuticals in collaboration with Sanofi; ipilimumab was developed by Bristol Myers Squibb[1][3][5][6].
- Brand names
- LibtayoYervoy
- Other names
- REGN2810 + ipilimumabcemiplimab + ipilimumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on cemiplimab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemiplimab + ipilimumab.